PL357014A1 - Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract - Google Patents

Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Info

Publication number
PL357014A1
PL357014A1 PL01357014A PL35701401A PL357014A1 PL 357014 A1 PL357014 A1 PL 357014A1 PL 01357014 A PL01357014 A PL 01357014A PL 35701401 A PL35701401 A PL 35701401A PL 357014 A1 PL357014 A1 PL 357014A1
Authority
PL
Poland
Prior art keywords
gastro
treatment
inflammatory diseases
binding molecules
intestinal tract
Prior art date
Application number
PL01357014A
Other languages
English (en)
Polish (pl)
Inventor
Hansjoerg Adam
Lothar Farber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL357014A1 publication Critical patent/PL357014A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL01357014A 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract PL357014A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007911.1A GB0007911D0 (en) 2000-03-30 2000-03-30 Organic compounds
PCT/EP2001/003541 WO2001072845A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Publications (1)

Publication Number Publication Date
PL357014A1 true PL357014A1 (en) 2004-07-12

Family

ID=9888901

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01357014A PL357014A1 (en) 2000-03-30 2001-03-28 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract

Country Status (18)

Country Link
US (2) US20050226872A1 (cg-RX-API-DMAC7.html)
EP (1) EP1268553A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528890A (cg-RX-API-DMAC7.html)
KR (2) KR20020084107A (cg-RX-API-DMAC7.html)
CN (1) CN1416432A (cg-RX-API-DMAC7.html)
AU (2) AU2001246516B2 (cg-RX-API-DMAC7.html)
BR (1) BR0109549A (cg-RX-API-DMAC7.html)
CA (1) CA2401249A1 (cg-RX-API-DMAC7.html)
GB (1) GB0007911D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0301846A3 (cg-RX-API-DMAC7.html)
IL (1) IL151089A0 (cg-RX-API-DMAC7.html)
NO (1) NO20024579L (cg-RX-API-DMAC7.html)
NZ (1) NZ520547A (cg-RX-API-DMAC7.html)
PL (1) PL357014A1 (cg-RX-API-DMAC7.html)
RU (1) RU2286797C2 (cg-RX-API-DMAC7.html)
SK (1) SK13892002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001072845A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200207736B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
WO2009086197A1 (en) * 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
RU2500427C2 (ru) * 2010-07-15 2013-12-10 Олег Ильич Эпштейн Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DE69937057T2 (de) * 1998-07-27 2008-05-29 Novartis Ag Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen

Also Published As

Publication number Publication date
RU2286797C2 (ru) 2006-11-10
NO20024579D0 (no) 2002-09-24
IL151089A0 (en) 2003-04-10
AU2001246516B2 (en) 2005-06-30
CA2401249A1 (en) 2001-10-04
NZ520547A (en) 2005-04-29
RU2002127800A (ru) 2004-03-27
WO2001072845A1 (en) 2001-10-04
US20050226872A1 (en) 2005-10-13
SK13892002A3 (sk) 2003-05-02
HUP0301846A3 (en) 2010-07-28
CN1416432A (zh) 2003-05-07
KR20080079702A (ko) 2008-09-01
ZA200207736B (en) 2003-05-08
EP1268553A1 (en) 2003-01-02
KR20020084107A (ko) 2002-11-04
GB0007911D0 (en) 2000-05-17
JP2003528890A (ja) 2003-09-30
NO20024579L (no) 2002-11-11
US20090041775A1 (en) 2009-02-12
HUP0301846A2 (hu) 2003-09-29
BR0109549A (pt) 2003-06-10
AU4651601A (en) 2001-10-08

Similar Documents

Publication Publication Date Title
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
IL150628A0 (en) Use of lipid conjugates in the treatment of disease
EP1764370A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
AP2002002690A0 (en) Antibody molecules having specificity for human tumor necrosis factor alphs and use thereof
IL181706A0 (en) The treatment of inflammatory disorders and pain
AU7296801A (en) Il-17 molecules and uses thereof
IL157136A0 (en) Therapeutic binding molecules
SI1432701T1 (sl) Uporaba heterociklicnih spojin pri zdravljenju bolezni urinarnega trakta
HUP0301846A3 (en) Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
IL173820A0 (en) Therapeutic binding molecules
AU2001287272A1 (en) Genes involved in intestinal inflammatory diseases and use thereof
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
IL181240A0 (en) Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
TWI372060B (en) Nogo-a binding molecules and pharmaceutical use thereof
EP1805210A4 (en) NOVEL PEPTIDES AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE
HUP0400986A3 (en) Use of cd25 binding molecules in steroid-resistant patients
GB0115780D0 (en) Therapeutic molecules and uses thereof
IL160310A0 (en) The use of anthroquinones in the treatment of kidney disease
IL154168A0 (en) Improved specificity in treatment of diseases
ZA200700668B (en) Use of cell-specific conjugates for treatment of Inflammatory diseases of the gastrointestinal tract
HK1057754A (en) Compounds useful in the treatment of inflammatory diseases
AU2728301A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
HK1062405A (en) The use of anthroquinones in the treatment of kidney disease
HK1104958A (en) Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)